US 2025/0019441 A1Published application

Treatment of cancer with anti-ilt2 antibodies

AssigneesBiond Biologics Ltd., Genzyme Corporation

InventorsDana Haves Ziv, Liat Tevel, Enas Halumi, Nyra Goldstein, Tsuri Peretz, Ilana Goldshtein, Tal Gabay, Anna Fridam-Dror, Itay Friedman, Sharon Hashmueli, Motti Hakim, Ilana Mandel, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe, Giovanni Abbadessa, Meijing Wu, Nigel Patrick Somerville Crawford, Rui Wang, Maria Agarwal, Cecilia Deantonio, Raymond Perez, Ji Lin

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention relates to treatment of cancer using an anti-human ILT2 monoclonal antibody. The treatment may additionally comprise pembrolizumab, optionally with chemotherapy, or cetuximab.

Claims21

Dependent claims

1-42. (canceled)

Dependencies are inferred from the claim text.

Facts

Application: 18/770,474Filed 11 Jul 2024
Priority: 11 Jul 2023
Published: 16 Jan 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/135
Amines: having aromatic rings , e.g. ketamine, nortriptyline

Family

Application63/513,037Us provisional application · filed 11 Jul 2023
Application63/550,356Us provisional application · filed 6 Feb 2024
Application63/643,156Us provisional application · filed 6 May 2024
US 2025/0019441 A1This patent

From the US filing history. Foreign family members aren’t listed.